StocksFundsScreenerSectorsWatchlists
SNTI

SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

0.34USD-0.01 (-2.86%)Market Closed

Market Summary

SNTI
USD0.34-0.01
Market Closed
-2.86%

SNTI Stock Price

View Fullscreen

SNTI RSI Chart

SNTI Valuation

Market Cap

15.6M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

6.07

Price/Free Cashflow

-0.24

SNTI Price/Sales (Trailing)

SNTI Profitability

Return on Equity

-184.42%

Return on Assets

-103.28%

Free Cashflow Yield

-414.18%

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

SNTI Earnings

Earnings (TTM)

-123.4M

Earnings Growth (Yr)

-22.07%

Earnings Growth (Qtr)

-376.16%

Breaking Down SNTI Revenue

Last 30 days

-12.8%

Last 90 days

-37.0%

How does SNTI drawdown profile look like?

SNTI Financial Health

Current Ratio

5.62

SNTI Investor Care

Shares Dilution (1Y)

3.81%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.5M4.0M2.6M2.6M
20223.8M4.4M5.0M4.3M
20211.1M1.7M2.2M2.8M
2020000566.0K

Tracking the Latest Insider Buys and Sells of Senti Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
rajangam kanya
acquired
-
-
101,000
chief medical & devt. officer
Feb 01, 2024
lu timothy k
acquired
-
-
306,000
ceo and president
Feb 01, 2024
knobelman deborah
acquired
-
-
101,000
chief financial officer
Oct 03, 2022
knobelman deborah
acquired
-
-
30,000
chief financial officer
Jun 08, 2022
epstein david r
acquired
-
-
112,519
-
Jun 08, 2022
farokhzad omid
acquired
-
-
5,750,000
-
Jun 08, 2022
farokhzad omid
acquired
2,500,000
10.00
250,000
-
Jun 08, 2022
farokhzad omid
sold
-
-
-4,518,100
-
Jun 08, 2022
dynamics sponsor llc
acquired
-
-
5,750,000
-
Jun 08, 2022
dynamics sponsor llc
sold
-
-
-6,465,500
-

1–10 of 10

Which funds bought or sold SNTI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
27.82
238,202
466,654
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
50.00
5,770
9,900
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
sold off
-100
-1,337,000
-
-%
Feb 14, 2024
NEA Management Company, LLC
unchanged
-
1,093,260
2,921,260
0.20%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
28,844
28,844
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-
-
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
34,118
95,700
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
new
-
18,904
18,904
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
9,514
9,514
-%

1–10 of 33

Are Funds Buying or Selling SNTI?

Are funds buying SNTI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SNTI
No. of Funds

Unveiling Senti Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
woodline partners lp
0%
0
SC 13G/A

Recent SEC filings of Senti Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Mar 21, 2024
8-K
Current Report
Mar 21, 2024
10-K
Annual Report
Feb 06, 2024
8-K
Current Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Jan 10, 2024
S-8
Employee Benefits Plan
Jan 05, 2024
8-K
Current Report

Peers (Alternatives to Senti Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.9B
6.8B
-4.35% -31.01%
-8.68
5.98
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
2.23% -24.84%
-43.61
10.5
76.23% 61.08%
17.0B
2.4B
4.87% -7.82%
101.5
7.03
15.42% 18.43%
12.4B
3.7B
-9.49% -25.82%
20.67
3.34
8.87% 75.42%
MID-CAP
6.9B
396.6M
-6.36% -28.65%
-12.96
17.28
425.83% 18.94%
4.8B
-
-5.56% 77.93%
-7.36
60.35
54.84% -34.79%
3.4B
270.6M
0.03% 16.25%
-14.05
12.42
440.80% -27.84%
3.1B
240.7M
-13.61% -3.16%
-10.6
13.07
-1.03% -92.09%
2.9B
726.4M
-26.61% -2.10%
-47.61
4.02
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-1.37% -9.52%
26.21
4.7
85.90% -14.05%
596.2M
983.7M
-16.96% -52.88%
-1.09
0.61
-50.36% 17.16%
400.4M
881.7K
-0.31% 365.37%
-8.98
466.16
-77.61% -5.33%
268.8M
4.9M
-4.49% 31.28%
-1.99
55.23
-54.97% 51.72%
7.0M
2.1M
71.19% 77.19%
-0.26
2.14
-13.45% 66.37%

Senti Biosciences, Inc. News

Latest updates
TradingView22 Mar 202402:53 am
InvestorPlace21 Mar 202407:00 am

Senti Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue-100.0%-3389371,28659.001,7661,3581,1047931,10379372.00-
Operating Expenses-68.2%14,04044,21420,57221,12023,90416,51423,12912,86211,67812,5269,7899,214-
  S&GA Expenses-6.5%8,8149,4319,6209,80212,0769,99513,8825,2595,2697,1164,5544,311-
  R&D Expenses-45.5%4,9559,09210,95211,31811,8296,5199,2477,6036,4095,4105,2354,903-
Net Income-376.2%-71,058-14,923-18,697-18,722-58,210-16,640-11,552-11,808-10,904-11,406-12,007-21,002-
Net Income Margin-14.2%-48.18*-42.20*-27.74*-23.53*-22.91*-10.14*-10.48*-12.16*-20.04*-8.98*-11.94*-17.82*-35.09*
Free Cashflow59.2%-7,041-17,237-17,344-22,811-17,539-24,337-16,955-17,439-15,956-9,737-1,354-8,571-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q22021Q12021Q12020Q4
Assets-9.3%11913214416118118920292.0097.0023223223217111048.00
  Current Assets-9.9%71.0079.0063.0081.0010312014445.0060.002.002.002.00--32.00
    Cash Equivalents0.0%39.0039.0037.0032.0058.0011514038.0059.0074.0083.002.0026.00-31.00
  Net PPE-4.1%25.0026.0059.0059.0051.0047.0036.0024.0012.00-----3.00
Liabilities7.7%53.0049.0046.0049.0054.0049.0048.0042.0036.008.008.008.0011.0014.0017.00
  Current Liabilities25.3%13.0010.0010.0013.0018.0016.0018.0018.0015.000.000.000.00--5.00
Shareholder's Equity-19.3%67.0083.0097.00112127140154--111-5.00-0.00--
  Retained Earnings-8.3%-244-225-210-192-173-155-138-126-115-6.52-6.23-6.000.000.00-59.80
  Additional Paid-In Capital0.9%3113093083043012952935.004.00---0.000.001.00
Accumulated Depreciation17.8%6.005.004.003.003.003.002.002.002.00-----1.00
Shares Outstanding2.7%46.0044.0044.0044.0044.0043.0013.003.003.003.003.00-15.005.0014.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q4
Cashflow From Operations54.2%-7,037-15,379-13,675-16,304-9,006-10,136-5,695-10,059-11,971-8,805-934-8,365--
  Share Based Compensation404.6%2,0644093,4343,7634,2162,2909,225661735626562372--
Cashflow From Investing-99.5%10121,14218,331-9,497-49,118-14,201-11,260-7,380---230,000-206--
Cashflow From Financing2517.4%556-23.00281-35.00876-485118,615-455--232,0323,558--

SNTI Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue  
Contract revenue$ 1,978$ 3,286
Grant income5831,000
Total revenue2,5614,286
Operating expenses  
Research and development (included related party cost of $3,113 and $—, respectively)32,15028,145
General and administrative37,17638,225
Loss on impairment of fixed assets25,9620
Total operating expenses95,28866,370
Loss from operations(92,727)(62,084)
Other income (expense)  
Interest income, net2,8641,701
Change in fair value of contingent earnout liability2079,461
Gain on extinguishment of convertible notes01,289
GeneFab sublease income - related party2,3230
Other income (expense)(33)(32)
Total other income (expense), net9,32112,419
Net loss from continuing operations(83,406)(49,665)
Net income (loss) from discontinued operations12,348(8,545)
Net loss(71,058)(58,210)
Other comprehensive gain (loss)  
Unrealized gain (loss) on investments(1)1
Comprehensive loss$ (71,059)$ (58,209)
Net loss per share from continuing operations, basic (in dollars per share)$ (1.88)$ (1.90)
Net loss per share from continuing operations, diluted (in dollars per share)(1.88)(1.90)
Net income (loss) per share from discontinued operations, basic (in dollars per share)0.28(0.33)
Net income (loss) per share from discontinued operations, diluted (in dollars per share)0.28(0.33)
Net loss per share, basic (in dollars per share)(1.60)(2.23)
Net loss per share, diluted (in dollars per share)$ (1.60)$ (2.23)
Weighted-average shares outstanding, basic (in shares)44,372,22326,110,785
Weighted-average shares outstanding, diluted (in shares)44,372,22326,110,785
GeneFab Option  
Other income (expense)  
Change in fair value$ 3,318$ 0
GeneFab Note Receivable  
Other income (expense)  
Change in fair value6260
GeneFab Economic Share  
Other income (expense)  
Change in fair value$ 16$ 0

SNTI Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 35,926$ 57,621
Short-term investments040,942
Current assets of discontinued operations0209
Total current assets71,200102,579
Restricted cash3,5223,366
GeneFab receivable - related party, net of current portion1,1190
Property and equipment, net25,33851,361
Operating lease right-of-use assets16,27418,418
GeneFab Economic Share - related party1,8160
Other long-term assets215283
Noncurrent assets of discontinued operations04,785
Total assets119,484180,792
Liabilities and Stockholders’ Equity  
Accounts payable1,2501,370
Finance lease liabilities, current portion970
Early exercise liability, current portion135135
Deferred revenue0799
GeneFab sublease deferred income - related party9890
Accrued expenses and other current liabilities5,92712,576
Operating lease liabilities4,0311,988
Current liabilities of discontinued operations2431,185
Total current liabilities12,67218,053
Operating lease liabilities, net of current portion33,53835,103
Contingent earnout liability20227
GeneFab Option - related party6,3310
Early exercise liability, net of current portion10146
Total liabilities52,57153,529
Commitments and contingencies (Note 15)
Stockholders’ equity:  
Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022; 45,700,161 and 44,062,534 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively54
Additional paid-in capital311,252300,544
Accumulated other comprehensive income01
Accumulated deficit(244,344)(173,286)
Total stockholders’ equity66,913127,263
Total liabilities, redeemable convertible preferred stock and stockholders’ equity119,484180,792
Nonrelated Party  
Assets  
Accounts receivable112626
Prepaid expenses and other current assets2,7833,181
Related Party  
Assets  
Accounts receivable17,5920
Prepaid expenses and other current assets$ 14,787$ 0
SNTI
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEsentibio.com
 INDUSTRYBiotechnology
 EMPLOYEES122

Senti Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Senti Biosciences, Inc.? What does SNTI stand for in stocks?

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Senti Biosciences, Inc. (SNTI)?

As of Wed Apr 10 2024, market cap of Senti Biosciences, Inc. is 15.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers. The fair value of Senti Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Senti Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Senti Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNTI is over valued or under valued. Whether Senti Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Senti Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNTI.

What is Senti Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 10 2024, SNTI's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 6.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.